Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Zealand hosts conference call on May 16 at 4 pm CET/10 am EDT to present first quarter results 2018

Zealand Pharma
Posted on: 14 May 18

Press Release - No. 12 / 2018

  Zealand hosts conference call on May 16 at 4 pm CET/10 am EDT to present first quarter results 2018

Copenhagen, May 14, 2017 - Zealand Pharma A/S ("Zealand") (CVR no. 20 04 50 78) announces that it will be hosting a conference call on May 16, 2018 at 4 pm CET/10 am EDT following the announcement of its Q1 2018 results.

Participating in the call will be President and Chief Executive Officer Britt Meelby Jensen, Executive Vice President and Chief Financial Officer Mats Blom and Executive Vice President and Chief Medical and Development Officer Adam Steensberg. The presentation will be followed by a Q&A session. The conference call will be conducted in English, and the dial-in numbers are:

Denmark                              +45 35 15 81 21
United Kingdom                   +44 (0)330 336 9411
United States                       +1 323 994 2083
Passcode                             1711773

A live audio webcast of the call, including an accompanying slide presentation, will be available via the following link, - also accessible from the Investor section of Zealand's website ( ). Participants are advised to register for the webcast approximately 10 minutes before the start. A recording of the event will be made available on the Investor section of Zealand's website after the call.

For further information, please contact:

Britt Meelby Jensen, President and Chief Executive Officer
Tel: +45 51 67 61 28, e-mail:

Mats Blom, Executive Vice President, Chief Financial Officer
Tel: +45 31 53 79 73, e-mail:

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a late stage clinical portfolio of proprietary product candidates focusing on specialty gastrointestinal and metabolic diseases. In addition, it has two marketed products, commercialized by Sanofi, and two product candidates under license collaboration with Boehringer Ingelheim.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit or follow Zealand on LinkedIn or Twitter @ZealandPharma.

12-18_0514- Q12018 Conference call

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Zealand Pharma via GlobeNewswire

Last updated on: 15/05/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.